Document Detail


Integration of 3-Dimensional Scar Models from SPECT to Guide Ventricular Tachycardia Ablation.
MedLine Citation:
PMID:  22577237     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The integration of myocardial scar models in 3-dimensional (3D) mapping systems may provide a novel way of helping to guide ventricular tachycardia (VT) ablations. This study assessed the value of (201)Tl SPECT perfusion imaging to define ventricular myocardial scar areas and to characterize electrophysiology voltage-derived myocardial substrate categories of scar, border zone (BZ), and normal myocardium regions. Scar and BZ regions have been implicated in the genesis of ventricular arrhythmias. METHODS: Ten patients scheduled for VT ablation underwent (201)Tl SPECT before the ablation procedure. 3D left ventricular (LV) scar models were created from the SPECT images. These scar models were registered with the LV voltage maps and analyzed with a 17-segment cardiac model. Scar location and scar burden were compared between the SPECT scar models and voltage maps. In addition, (201)Tl SPECT uptake was quantified using a 68-segment cardiac model and compared among voltage-defined scar, BZ, and normal segments. RESULTS: 3D models of LV myocardium and scar were successfully created from (201)Tl SPECT images and integrated in a clinical mapping system. The surface registration error with the electrophysiology voltage map was 4.4 ± 1.0 mm. The 3D scar location from SPECT matched in 72% of the segments with the voltage map findings. All successful ablation sites were located within the SPECT-defined scar or within 1 cm of its border, with 73% of the successful ablation sites within 1 cm of the scar border. Voltage measurements in SPECT-defined scar and normal areas were 1.2 ± 1.7 and 3.4 ± 2.8 mV, respectively (P < 0.001). The fractional SPECT scar burden area (18.8% ± 5.2%) agreed better with the abnormal (scar plus BZ) voltage area (20.8% ± 15.7%) than with the scar voltage area (5.8% ± 5.8%). Mean normalized (201)Tl uptake was 55% ± 21% in the voltage-defined scar, 63% ± 20% in BZ, and 79% ± 17% in normal myocardial segments (P < 0.05 for scar or BZ vs. normal). CONCLUSION: 3D SPECT surface models of LV scar were accurately integrated into a clinical mapping system and predicted endocardial voltage-defined scar. These preliminary data support the possible use of widely available (201)Tl SPECT to facilitate substrate-guided VT ablations.
Authors:
Jing Tian; Mark F Smith; Ghada Ahmad; Vasken Dilsizian; Alejandro Jimenez; Timm Dickfeld
Related Documents :
16999647 - Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no...
2513427 - The complement system in the acute phase of myocardial infarction.
6103327 - Chlorpromazine and frusemide in treatment of acute left-ventricular failure.
5558187 - Acute myocardial infarction: home and hospital treatment.
12649617 - Bypass injury: implications of cardiopulmonary bypass.
18764947 - Severe accordion effect: myocardial ischemia due to wire complication during percutaneo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-10
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  -     ISSN:  1535-5667     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Radiosynthesis and Preclinical Evaluation of 18F-F13714 as a Fluorinated 5-HT1A Receptor Agonist Rad...
Next Document:  Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease an...